Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Ash 2022 – Affimed feels the pain
Affimed investors find that what goes up must come down, though the stock owes only part of its fall to an Ash presentation.
Ash 2022 preview – Affimed and Aptose score
In oncology settings outside multiple myeloma investors have picked two early winners.
Fourth-quarter data for the little guys
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
AACR 2022 – A weekend of updates yields few winners
The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.
AACR 2022 – Affimed shows that 2021 was no fluke
An academic-sponsored trial gives Affimed’s NK cell engaging approach a huge endorsement.
